{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T10:41:29Z","timestamp":1786790489920,"version":"build-2736575974"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Dexamethasone sodium phosphate (DSP) encapsulated in autologous erythrocytes (EryDex) was developed as an alternative to standard glucocorticoids in an effort to eliminate chronic steroid toxicity while preserving efficacy. The primary objective of this report is to describe the safety of long-term use of EryDex in treatment of pediatric patients with ataxia telangiectasia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This is a post-hoc analysis of patients treated with EryDex for a minimum of 24\u202fmonths in two prospective clinical trials. Outcomes include adverse events, growth, hemoglobin and serum iron, glucose levels, HbA1c, CD4+ lymphocytes, and bone mineral density.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Sixty-eight patients completed a minimum of 2\u202fyears of treatment with EryDex (mean treatment length 39\u202f\u00b1\u202f11\u202fmonths). Treatment-emergent adverse events (TEAE), reported in 67 (99%) out of 68 patients, were typically mild and did not cause discontinuation of treatment or death. Treatment-related TEAE were noted in 48 (71%) patients. Notable adverse events included transient pruritus reported in 23 (34%) patients and findings of low serum iron reported in 27 (40%) patients, while at baseline one fifth of patients had low serum iron. Anemia was reported in 9 (13%) patients. The mean hemoglobin level changed by \u22120.8\u202f\u00b1\u202f1.0\u202fg\/dL after 6\u202fmonths of therapy without subsequent decline. Longitudinal height and weight mean z-scores showed minimal change from baseline to month 24 for height (\u22120.06\u202f\u00b1\u202f0.49), weight (\u22120.02\u202f\u00b1\u202f0.71), and body mass index (0.03\u202f\u00b1\u202f0.87). The mean bone mineral density (BMD) z-score showed a decline of 0.4 points over the 24\u202fmonths of treatment. Values for glucose, HbA1c, cortisol, and CD4+ lymphocyte counts did not show clinically significant changes during prolonged treatment with EryDex.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The most common treatment-related adverse events were transient infusion-related pruritus and iron deficiency. There was a decline in BMD which could not be distinguished from the natural course of disease. There were no adverse effects on height, weight and body mass index noted, as documented by stable z-scores throughout the 2\u202fyears of treatment. Adverse events typically observed with prolonged glucocorticoid use such as Cushingoid features, weight gain, hypertension, hirsutism, diabetes or stunted growth were rarely reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical trial registration<\/jats:title><jats:p><jats:ext-link>ClinicalTrials.gov<\/jats:ext-link>, identifiers: NCT02770807 and NCT03563053.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2024.1526914","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T14:34:36Z","timestamp":1737642876000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Long-term safety of dexamethasone sodium phosphate encapsulated in autologous erythrocytes in pediatric patients with ataxia telangiectasia"],"prefix":"10.3389","volume":"15","author":[{"given":"Mary Kay","family":"Koenig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Leuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riadh","family":"Gouider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eppie M.","family":"Yiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Pietrucha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asbj\u00f8rg","family":"Stray-Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan L.","family":"Perlman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trudy","family":"Burgers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupam","family":"Borgohain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rukmini Mridula","family":"Kandadai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Meyts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Bucciol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anaita","family":"Udwadia-Hegde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Dane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Roden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Thye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biljana","family":"Horn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard M.","family":"Lederman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William P.","family":"Whitehouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,23]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/336577a0","article-title":"Localization of an Ataxia-telangiectasia gene to chromosome 11q22-23","volume":"336","author":"Gatti","year":"1988","journal-title":"Nature"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1038\/s41580-021-00394-2","article-title":"Cellular functions of the protein kinase Atm and their relevance to human disease","volume":"22","author":"Lee","year":"2021","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s13023-016-0543-7","article-title":"Ataxia telangiectasia: a review","volume":"11","author":"Rothblum-Oviatt","year":"2016","journal-title":"Orphanet J Rare Dis"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"e0264177","DOI":"10.1371\/journal.pone.0264177","article-title":"The natural history of ataxia-telangiectasia (a-T): a systematic review","volume":"17","author":"Petley","year":"2022","journal-title":"PLoS One"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/pai.13020","article-title":"Ataxia-telangiectasia: a review of clinical features and molecular pathology","volume":"30","author":"Amirifar","year":"2019","journal-title":"Pediatr Allergy Immunol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1007\/s10875-022-01352-z","article-title":"The 2022 update of iuis phenotypical classification for human inborn errors of immunity","volume":"42","author":"Bousfiha","year":"2022","journal-title":"J Clin Immunol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"4757","DOI":"10.4049\/jimmunol.178.8.4757","article-title":"Regulation of oxidative stress responses by ataxia-telangiectasia mutated is required for T cell proliferation","volume":"178","author":"Bagley","year":"2007","journal-title":"J Immunol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1007\/s10875-021-01090-8","article-title":"Simple measurement of Iga predicts immunity and mortality in ataxia-telangiectasia","volume":"41","author":"Zielen","year":"2021","journal-title":"J Clin Immunol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"272","DOI":"10.55133\/eji.280428","article-title":"Clinical and immunological assessment of children with Ataxia telangiectasia attending Sohag University Hospital in Upper Egypt","volume":"28","author":"Fahmy","year":"2021","journal-title":"Egypt J Immunol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/j.1365-2249.2006.03221.x","article-title":"Impaired interferon-gamma production in response to live bacteria and toll-like receptor agonists in patients with ataxia telangiectasia","volume":"146","author":"Reichenbach","year":"2006","journal-title":"Clin Exp Immunol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1046\/j.1365-2249.2002.01830.x","article-title":"Deficiencies in Cd4+ and Cd8+ T cell subsets in ataxia telangiectasia","volume":"129","author":"Schubert","year":"2002","journal-title":"Clin Exp Immunol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1136\/adc.2008.149351","article-title":"Ataxia-telangiectasia patients presenting with hyper-Igm syndrome","volume":"94","author":"Noordzij","year":"2009","journal-title":"Arch Dis Child"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"972952","DOI":"10.3389\/fped.2022.972952","article-title":"Infections and immune dysregulation in Ataxia-telangiectasia children with hyper-Igm and non-hyper-Igm phenotypes: a single-center experience","volume":"10","author":"Szczawinska-Poplonyk","year":"2022","journal-title":"Front Pediatr"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1111\/j.1468-1331.2009.02600.x","article-title":"In Ataxia-Teleangiectasia betamethasone response is inversely correlated to cerebellar atrophy and directly to Antioxidative capacity","volume":"16","author":"Russo","year":"2009","journal-title":"Eur J Neurol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"3962","DOI":"10.1111\/febs.13901","article-title":"Dexamethasone improves redox state in Ataxia telangiectasia cells by promoting an Nrf2-mediated antioxidant response","volume":"283","author":"Biagiotti","year":"2016","journal-title":"FEBS J"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1001\/archneur.63.10.1479","article-title":"Betamethasone and improvement of neurological symptoms in Ataxia-telangiectasia","volume":"63","author":"Buoni","year":"2006","journal-title":"Arch Neurol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/j.1468-1331.2008.02060.x","article-title":"Steroid-induced improvement of neurological signs in Ataxia-telangiectasia patients","volume":"15","author":"Broccoletti","year":"2008","journal-title":"Eur J Neurol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1111\/j.1468-1331.2010.03203.x","article-title":"Efficacy of very-low-dose betamethasone on neurological symptoms in Ataxia-telangiectasia","volume":"18","author":"Broccoletti","year":"2011","journal-title":"Eur J Neurol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1002\/mds.25126","article-title":"A randomized trial of oral betamethasone to reduce Ataxia symptoms in Ataxia telangiectasia","volume":"27","author":"Zannolli","year":"2012","journal-title":"Mov Disord"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.pediatrneurol.2019.05.006","article-title":"Long-term evaluation of low-dose betamethasone for Ataxia telangiectasia","volume":"100","author":"Hasegawa","year":"2019","journal-title":"Pediatr Neurol"},{"key":"ref21","author":"Nicolaides","year":"2018"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"e0216668","DOI":"10.1371\/journal.pone.0216668","article-title":"Activation of Nrf2 by dexamethasone in Ataxia telangiectasia cells involves Keap1 inhibition but not the inhibition of P38","volume":"14","author":"Biagiotti","year":"2019","journal-title":"PLoS One"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s11010-017-3122-x","article-title":"In vivo effects of dexamethasone on blood gene expression in Ataxia telangiectasia","volume":"438","author":"Menotta","year":"2018","journal-title":"Mol Cell Biochem"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s11010-014-2013-7","article-title":"Forward subtractive libraries containing genes Transactivated by dexamethasone in Ataxia-telangiectasia Lymphoblastoid cells","volume":"392","author":"Biagiotti","year":"2014","journal-title":"Mol Cell Biochem"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s13023-017-0669-2","article-title":"Atm splicing variants as biomarkers for low dose dexamethasone treatment of a-T","volume":"12","author":"Menotta","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"759467","DOI":"10.3389\/fgene.2021.759467","article-title":"Functional classification of the Atm variant C.7157c>a and in vitro effects of dexamethasone","volume":"12","author":"Biagiotti","year":"2021","journal-title":"Front Genet"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"41352","DOI":"10.1074\/jbc.M112.344473","article-title":"Dexamethasone partially rescues Ataxia telangiectasia-mutated (Atm) deficiency in Ataxia telangiectasia by promoting a shortened protein variant retaining kinase activity","volume":"287","author":"Menotta","year":"2012","journal-title":"J Biol Chem"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.ijpharm.2016.12.011","article-title":"Ex vivo encapsulation of dexamethasone sodium phosphate into human autologous erythrocytes using fully automated biomedical equipment","volume":"517","author":"Mambrini","year":"2017","journal-title":"Int J Pharm"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.tmrv.2017.09.001","article-title":"A study of the pharmacokinetic properties and the in vivo kinetics of erythrocytes loaded with dexamethasone sodium phosphate in healthy volunteers","volume":"32","author":"Coker","year":"2018","journal-title":"Transfus Med Rev"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1750-1172-9-5","article-title":"Intra-erythrocyte infusion of dexamethasone reduces neurological symptoms in Ataxia Teleangiectasia patients: results of a phase 2 trial","volume":"9","author":"Chessa","year":"2014","journal-title":"Orphanet J Rare Dis"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"e98","DOI":"10.1212\/NXI.0000000000000098","article-title":"Positive effect of erythrocyte-delivered dexamethasone in Ataxia-telangiectasia","volume":"2","author":"Leuzzi","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/S1474-4422(24)00220-5","article-title":"Safety and efficacy of intra-erythrocyte dexamethasone sodium phosphate in children with Ataxia telangiectasia (Attest): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial","volume":"23","author":"Zielen","year":"2024","journal-title":"Lancet Neurol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.jocd.2014.10.001","article-title":"International society for clinical densitometry. 2013 pediatric position development conference: executive summary and reflections","volume":"17","author":"Gordon","year":"2014","journal-title":"J Clin Densitom"},{"key":"ref34","year":"2017"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.jpeds.2003.12.046","article-title":"Immunodeficiency and infections in Ataxia-telangiectasia","volume":"144","author":"Nowak-Wegrzyn","year":"2004","journal-title":"J Pediatr"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/BF03018722","article-title":"Perineal pruritus after iv dexamethasone administration (letter)","volume":"50","author":"Perron","year":"2003","journal-title":"Can J Anesth"},{"key":"ref37","first-page":"1015","article-title":"The effect of dilution and prolonged injection time on dexamethasone-induced perineal pruritus","volume":"67","author":"Gu","year":"2012","journal-title":"Pharmazie"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1038\/s41418-019-0393-7","article-title":"Kinome screen of Ferroptosis reveals a novel role of Atm in regulating Iron metabolism","volume":"27","author":"Chen","year":"2020","journal-title":"Cell Death Differ"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jped.2018.07.014","article-title":"Effect of prednisolone on linear growth in children with nephrotic syndrome","volume":"96","author":"Valavi","year":"2020","journal-title":"J Pediatr"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s13023-021-01716-5","article-title":"Growth in Ataxia telangiectasia","volume":"16","author":"Natale","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1093\/hmg\/ddl116","article-title":"Atm-deficient mice: an osteoporosis model with defective osteoblast differentiation and increased Osteoclastogenesis","volume":"15","author":"Rasheed","year":"2006","journal-title":"Hum Mol Genet"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"eaaw4626","DOI":"10.1126\/scitranslmed.aaw4626","article-title":"Impaired Atm activation in B cells is associated with bone resorption in rheumatoid arthritis","volume":"11","author":"Mensah","year":"2019","journal-title":"Sci Transl Med"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1526914\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T14:34:38Z","timestamp":1737642878000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1526914\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,23]]},"references-count":42,"alternative-id":["10.3389\/fneur.2024.1526914"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2024.1526914","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,23]]},"article-number":"1526914"}}